Other languages C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-03 pm EDT			5-day change	1st Jan Change
4.84 ^USD	-3.01%		-11.68%	-14.34%

May. 09	Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating	MT
May. 08	C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates	May. 08
C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	Apr. 08
C4 Therapeutics Collaborating With Germany's Merck KGaA to Advance Research on Targeted Therapies for Cancer	Mar. 04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA Against Critical Oncogenic Proteins	Mar. 04
C4 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22
C4 Therapeutics Shares Jump After JPMorgan Upgrade	Jan. 29
Top Midday Gainers	Dec. 13
Sector Update: Health Care Stocks Flat Premarket Wednesday	Dec. 13
C4 Therapeutics Flags 'Promising' Early Data in Trial of Multiple Myeloma, Non-Hodgkin's Lymphomas Treatment	Dec. 13
Sector Update: Health Care Stocks Advance Late Afternoon	Dec. 12
C4 Therapeutics, Inc. Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma	Dec. 12
Sector Update: Health Care	Dec. 12
Top Midday Gainers	Dec. 12
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	Dec. 12
Investors Await Inflation Data, Look to Last Fed Meeting of Year as US Futures Rise Slightly in Tuesday's Premarket	Dec. 12
Top Premarket Gainers	Dec. 12
C4 Therapeutics, Inc. Appoints Owen Hughes to Its Board of Directors	Nov. 20
C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01
Top Premarket Decliners	23-10-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Other languages

Filters